Image pharmaphorum Editor Partner Content Partner Content 6th Annual 3D Cell Culture Conference www.3d-cellculture.com/PharmaphorumWL Digital Deep Dive: Digital Health 2022 Following an unprecedented year of surging investment interest, the digital health industry is booming. Views & Analysis Improving trial predictability: leveraging AI-powered analyt... Enrolling for clinical trials has become more challenging in recent years, with trial competition, increasingly complex protocols, and precision medicine targeting more niche patient popula Views & Analysis Steps to building a more patient-centric industry Lack of access, strict regulations, and demanding schedules have made it extremely difficult for patients to participate in clinical trials. Load more results
Partner Content Partner Content 6th Annual 3D Cell Culture Conference www.3d-cellculture.com/PharmaphorumWL
Digital Deep Dive: Digital Health 2022 Following an unprecedented year of surging investment interest, the digital health industry is booming.
Views & Analysis Improving trial predictability: leveraging AI-powered analyt... Enrolling for clinical trials has become more challenging in recent years, with trial competition, increasingly complex protocols, and precision medicine targeting more niche patient popula
Views & Analysis Steps to building a more patient-centric industry Lack of access, strict regulations, and demanding schedules have made it extremely difficult for patients to participate in clinical trials.
News Immunovant's thyroid eye disease drug flunks pivotal trials Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
